LEADER 02612oam 2200757I 450 001 9910709608803321 005 20180613095220.0 035 $a(CKB)5470000002472153 035 $a(OCoLC)760946604 035 $a(EXLCZ)995470000002472153 100 $a20111114j198505 ua 0 101 0 $aeng 135 $aurun||||a|a|| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aTotal energy-rate feedback for automatic glide-slope tracking during wind-shear penetration /$fChristine M. Belcastro and Aaron J. Ostroff 210 1$aWashington, D.C. :$cNational Aeronautics and Space Administration, Scientific and Technical Information Branch,$dMay 1985. 215 $a1 online resource (iii, 69 pages) $cillustrations 225 1 $aNASA technical paper ;$v2412 300 $a"May 1985." 300 $aPrepared at Langley Research Center. 320 $aIncludes bibliographical references (pages 36-37). 606 $aFeedback$2nasat 606 $aGlide paths$2nasat 606 $aAircraft landing$2nasat 606 $aWind shear$2nasat 606 $aLongitudinal control$2nasat 606 $aAirplanes$xLanding$xAutomatic control 606 $aFeedback control systems 606 $aWind shear 606 $aGust loads 606 $aStability of airplanes, Longitudinal 606 $aFeedback control systems$2fast 606 $aGust loads$2fast 606 $aStability of airplanes, Longitudinal$2fast 606 $aWind shear$2fast 615 7$aFeedback. 615 7$aGlide paths. 615 7$aAircraft landing. 615 7$aWind shear. 615 7$aLongitudinal control. 615 0$aAirplanes$xLanding$xAutomatic control. 615 0$aFeedback control systems. 615 0$aWind shear. 615 0$aGust loads. 615 0$aStability of airplanes, Longitudinal. 615 7$aFeedback control systems. 615 7$aGust loads. 615 7$aStability of airplanes, Longitudinal. 615 7$aWind shear. 700 $aBelcastro$b Christine M.$01408621 702 $aOstroff$b Aaron J. 712 02$aUnited States.$bNational Aeronautics and Space Administration.$bScientific and Technical Information Branch, 712 02$aLangley Research Center. 801 0$bOCLCE 801 1$bOCLCE 801 2$bOCLCQ 801 2$bOCLCO 801 2$bOCLCQ 801 2$bOCLCF 801 2$bGPO 906 $aBOOK 912 $a9910709608803321 996 $aTotal energy-rate feedback for automatic glide-slope tracking during wind-shear penetration$93492993 997 $aUNINA LEADER 03462nam 2200373z- 450 001 9910136804703321 005 20210211 035 $a(CKB)3710000000631093 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/54346 035 $a(oapen)doab54346 035 $a(EXLCZ)993710000000631093 100 $a20202102d2015 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aThe Natriuretic Hormones 210 $cFrontiers Media SA$d2015 215 $a1 online resource (76 p.) 225 1 $aFrontiers Research Topics 311 08$a2-88919-709-3 330 $aThe title follows from the original demonstration by Dr. Hugh de Wardener in 1961 that a humoral agent is produced after extracellular volume expansion which results in a vigorous diuresis and natriuresis. Thus the name of "natriuretic hormone" was coined. In the years that followed several investigators pursued the search for the hormone. What resulted, however, was the discovery of several hormones with different characteristics, all of which were natriuretic. Initially it was found that the hormone was similar in action to ouabain or digoxin, hence the appelation of ouabain-like or digoxin-like. The hormone was found to be an inhibitor of Na-K-ATPase, which would fit with it being a cardiotonic steroid. On the other hand, neither ouabain or digoxin migrated on Sephadex gel filtration in the same locus as the hormone. Other investigators claim to have identified the hormone-initially as a vanadium-diascorbate, later as bufadienolides such as marinobufagenin, yet later as a macrocylic derivative of inorganic carbon suboxide with a molecular weight of 408 Da. Some support for the latter finding was derived from an earlier report that a semi-purified Sephadex-derived compound was found to have a molecular weight of about 12,000 Da but the active compound, when split from its carrier protein, had a molecular weight of exactly 408 Da. This compound had not been further identified. As further development was the demonstration by Bricker and colleagues that a natriuretic substance could be purified from uremic urine. This turned out to be a xathurenic acid derivative. Meanwhile the focus began to turn to natriuretic peptides derived from heart (ANF and BNP). These peptides have a shorter duration of action than the cardiotonic steroid-like hormone and ANF has proved to be most useful as a measure of heart failure. It should also be stressed that marinobufagenin, like ANF, is elevated in congestive heart failure, whereas the steroid-like hormone is depressed or absent in this state. This review will attempt to describe and contrast the properties of each of the proposed natriuretic hormones, including their locus on Sephadex separation, potency, duration of action, chemical structure (if known), behavior in hypertension, renal failure, heart failure, and brain disease. As most recent work has focussed on marinobufagenin, this hormone will be brought up to date by investigators in the field. 610 $ahormone 610 $aHypertension 610 $aHypothalamus 610 $aNatriuresis 610 $aVolume expansion 700 $aVardaman M. Buckalew$4auth$01332386 702 $aHarvey Craig Gonick$4auth 906 $aBOOK 912 $a9910136804703321 996 $aThe Natriuretic Hormones$93040925 997 $aUNINA